Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?

Executive Summary

FDA plans to launch two "mini-Sentinel" pilot projects as the next steps towards building the active surveillance capability called for under the FDA Amendments Act of 2007, Sentinel Initiative Scientific Lead Judith Racoosin told a Sept. 2 Institute of Medicine meeting focused on the drug safety system post-FDAAA

You may also be interested in...



Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel

The recent Avandia safety panel meeting - during which two FDA advisory committees were unswayed by the results of an observational study by one of the agency's own scientists - underscores the challenges that FDA's Sentinel Initiative will have in becoming an essential regulatory tool

Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel

The recent Avandia safety panel meeting - during which two FDA advisory committees were unswayed by the results of an observational study by one of the agency's own scientists - underscores the challenges that FDA's Sentinel Initiative will have in becoming an essential regulatory tool

FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews

A June 23 memorandum of understanding on data sharing could serve as a first step toward parallel reviews by FDA and CMS for marketing approval and Medicare coverage, according to FDA

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel